Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia.

Al-Riyami AZ, Hudoba M, Young S, Forrest D.

Leuk Lymphoma. 2013 Aug;54(8):1788-90. doi: 10.3109/10428194.2012.749469. Epub 2012 Dec 26. No abstract available.

PMID:
23157309
2.

Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.

Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, Scheers W, Boogaerts M, Vandenberghe P, Marynen P, Cools J.

Blood. 2006 Aug 15;108(4):1374-6. Epub 2006 Apr 27.

3.

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.

Metzgeroth G, Erben P, Martin H, Mousset S, Teichmann M, Walz C, Klippstein T, Hochhaus A, Cross NC, Hofmann WK, Reiter A.

Leukemia. 2012 Jan;26(1):162-4. doi: 10.1038/leu.2011.181. Epub 2011 Aug 5. No abstract available.

PMID:
21818111
4.

A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.

Salemi S, Yousefi S, Simon D, Schmid I, Moretti L, Scapozza L, Simon HU.

Allergy. 2009 Jun;64(6):913-8. doi: 10.1111/j.1398-9995.2009.01943.x. Epub 2009 Feb 7.

5.

Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.

Shah S, Loghavi S, Garcia-Manero G, Khoury JD.

J Hematol Oncol. 2014 Mar 27;7:26. doi: 10.1186/1756-8722-7-26.

6.

Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.

Jain N, Khoury JD, Pemmaraju N, Kollipara P, Kantarjian H, Verstovsek S.

Blood. 2013 Nov 7;122(19):3387-8. doi: 10.1182/blood-2013-07-516500. No abstract available.

7.

The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.

Shen Y, Shi X, Pan J.

PLoS One. 2013 Aug 29;8(8):e73059. doi: 10.1371/journal.pone.0073059. eCollection 2013.

8.

Hes1 upregulation contributes to the development of FIP1L1-PDGRA-positive leukemia in blast crisis.

Uchida T, Kitaura J, Nakahara F, Togami K, Inoue D, Maehara A, Nishimura K, Kawabata KC, Doki N, Kakihana K, Yoshioka K, Izawa K, Oki T, Sada A, Harada Y, Ohashi K, Katayama Y, Matsui T, Harada H, Kitamura T.

Exp Hematol. 2014 May;42(5):369-379.e3. doi: 10.1016/j.exphem.2014.01.009. Epub 2014 Jan 31.

PMID:
24486648
9.

FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.

Lierman E, Michaux L, Beullens E, Pierre P, Marynen P, Cools J, Vandenberghe P.

Leukemia. 2009 May;23(5):845-51. doi: 10.1038/leu.2009.2. Epub 2009 Feb 12.

PMID:
19212337
10.

Complete response of monoblastic myeloid sarcoma with FIP1L1- PDGFRA rearrangement to imatinib monotherapy.

Srinivas U, Barwad A, Pubbaraju SV.

Br J Haematol. 2014 Jun;165(5):583. doi: 10.1111/bjh.12742. Epub 2014 Jan 24. No abstract available.

PMID:
24456122
11.

Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.

Helbig G, Kyrcz-Krzemień S.

Am J Hematol. 2014 Jan;89(1):115. doi: 10.1002/ajh.23588. Epub 2013 Oct 15. No abstract available.

12.

[FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review].

Qu SQ, Wang Y, Sun XJ.

Zhonghua Xue Ye Xue Za Zhi. 2013 Feb;34(2):159-61. Review. Chinese. No abstract available.

PMID:
23611226
13.

Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate.

Rathe M, Kristensen TK, Møller MB, Carlsen NL.

Pediatr Blood Cancer. 2010 Oct;55(4):730-2. doi: 10.1002/pbc.22655.

PMID:
20589620
14.

Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib.

Burbury K, Chew LP, Westerman D, Catalano A, Seymour JF.

Leuk Lymphoma. 2011 Feb;52(2):335-8. doi: 10.3109/10428194.2010.534210. No abstract available.

PMID:
21281241
15.

The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).

von Bubnoff N, Gorantla SP, Thöne S, Peschel C, Duyster J.

Blood. 2006 Jun 15;107(12):4970-1; author reply 4972. No abstract available.

16.

Complete and long-lasting cytologic and molecular remission of FIP1L1-PDGFRA-positive acute eosinophil myeloid leukaemia, treated with low-dose imatinib monotherapy.

Barraco D, Carobolante F, Candoni A, Simeone E, Piccaluga P, Tabanelli V, Fanin R.

Eur J Haematol. 2014 Jun;92(6):541-5. doi: 10.1111/ejh.12272. Epub 2014 Feb 19.

PMID:
24460680
17.

A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.

Chen D, Bachanova V, Ketterling RP, Begna KH, Hanson CA, Viswanatha DS.

Am J Surg Pathol. 2013 Jan;37(1):147-51. doi: 10.1097/PAS.0b013e31826df00b.

PMID:
23232855
18.

Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy.

Tang TC, Chang H, Chuang WY.

Acta Haematol. 2012;128(2):83-7. doi: 10.1159/000338217. Epub 2012 Jun 19.

PMID:
22722648
19.

The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.

von Bubnoff N, Gorantla SP, Engh RA, Oliveira TM, Thöne S, Aberg E, Peschel C, Duyster J.

Oncogene. 2011 Feb 24;30(8):933-43. doi: 10.1038/onc.2010.476. Epub 2010 Oct 25.

PMID:
20972453
20.

Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome.

Pardanani A, D'Souza A, Knudson RA, Hanson CA, Ketterling RP, Tefferi A.

Leukemia. 2012 Nov;26(11):2439-41. doi: 10.1038/leu.2012.162. Epub 2012 Jun 18. No abstract available.

PMID:
22705991

Supplemental Content

Support Center